USANA Health Sciences, Inc. (NYSE:USNA) Insider Sells $132,063.24 in Stock

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) insider Paul A. Jones sold 2,714 shares of USANA Health Sciences stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $48.66, for a total value of $132,063.24. Following the transaction, the insider now owns 6,266 shares in the company, valued at approximately $304,903.56. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

USANA Health Sciences Stock Performance

USANA Health Sciences stock traded down $0.74 during midday trading on Thursday, reaching $47.82. The stock had a trading volume of 54,526 shares, compared to its average volume of 79,646. The stock has a market capitalization of $910.97 million, a P/E ratio of 14.90, a price-to-earnings-growth ratio of 1.49 and a beta of 0.94. The firm's fifty day simple moving average is $46.31 and its 200-day simple moving average is $48.09. USANA Health Sciences, Inc. has a 1-year low of $41.45 and a 1-year high of $69.60.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.17. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. The company had revenue of $227.80 million for the quarter, compared to the consensus estimate of $223.27 million. On average, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, DA Davidson cut their price objective on shares of USANA Health Sciences from $48.00 to $46.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 7th.

Hedge Funds Weigh In On USANA Health Sciences

A number of large investors have recently modified their holdings of the business. Hsbc Holdings PLC acquired a new position in USANA Health Sciences during the third quarter valued at approximately $570,000. Pacer Advisors Inc. increased its holdings in USANA Health Sciences by 75.7% during the fourth quarter. Pacer Advisors Inc. now owns 337,371 shares of the company's stock worth $18,083,000 after buying an additional 145,373 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in USANA Health Sciences by 2.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 90,659 shares of the company's stock worth $5,314,000 after acquiring an additional 2,168 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in USANA Health Sciences by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 213,887 shares of the company's stock valued at $12,536,000 after acquiring an additional 8,084 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in shares of USANA Health Sciences by 7.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 16,534 shares of the company's stock valued at $886,000 after acquiring an additional 1,162 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.